Under the Amendment, the license granted by Tanabe to the Company related to lorundrostat was amended and restated to grant to the Company an exclusive, worldwide, royalty-free, sublicensable, perpet…
Pursuant to the Mitsubishi License, we paid Mitsubishi Tanabe a $1.0 million upfront fee and development milestone payments of $9.0 million in the aggregate.
mounts held primarily in interest-bearing money market accounts and U.S. Treasury bills with original maturities of less than three months. The Company’s cash and cash equivalents balances as of Dece…
Mineralys Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
MLYS-DEBT-11018
Warrants outstanding: 0.001
90%
xbrl warrant detail from xbrl 2024-02-07.
MLYS-DEBT-11019
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2023-12-31.
Mineralys Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Mineralys Therapeutics, Inc..
Mineralys Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
MLYS-OWNER-CATALYS-PACIFIC-LLC
Catalys Pacific, LLC
90%
13F overlay lists Catalys Pacific, LLC as top holder; 217 tracked holders.
Mineralys Therapeutics, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
